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Drug discovery is a dynamic yet an ever-lasting topic in medicine that heavily relies on the application of model 
organisms. Through the use of suitable model organisms, pre-clinical testing of new drug candidates can be carried 
out extensively prior to further testing with humans. This has been proven, so far, as one of eﬃcient ways to limit the 
emergence of new substances that are potentially harmful to individuals. Nevertheless, increasing public interest in the 
ethical issues raised by the use of live model organisms, such as mice and rats, pushes urgent needs for alternative model 
organisms. To this end, fruit ﬂy Drosophila melanogaster might be an appropriate model organism to be accounted for. 
With its long-standing history of use, Drosophila is an insect behind the revelation of striking similarity to humans as to 
basic biological mechanisms and their tight controls to maintain homeostasis. Impairment of such events in Drosophila 
is linked to the emergence of metabolic-related diseases such as obesity and diabetes mellitus, the unsolved cases of 
neurodegenerative diseases, and the fall of host immune responses against various infectious agents. With a high genetic 
similarity, about 75%, to humans, ease of maintenance, and the availability of various disease models constructed 
through genetic manipulation and/or chemical induction, Drosophila has been a very promising model organism in the 
ﬁeld of drug discovery. With this in mind, it would be not surprising if this tiny yet powerful model organism will soon 
substitute our current in vivo platform in the pre-clinical testing of new drug candidates.
INTRODUCTION
For the last decade, the emergence of sophisticated 
research tools, techniques, and model organisms in the 
ﬁeld of medical and pharmaceutical sciences has extraor-
dinarily advanced our understanding on the pathogenesis 
of diseases and their mechanisms at cellular and molecular 
levels that leads to the discovery of new eﬀective drugs. 
In drug discovery research, the use of model organisms 
as an in vivo platform at a pre-clinical level for testing 
new drug compounds is still a commonly used method 
(Breyer et al. 2015; McGonigle & Ruggeri, 2014; Ruggeri 
et al. 2014). Through the use of various model organisms, 
careful investigations regarding the pathophysiology of 
diseases along with pharmacologic approaches that can 
be used to treat these diseases can be achieved in a proper 
manner (Breyer et al. 2015; McGonigle & Ruggeri, 2014). 
In addition, model organisms are also very useful to 
provide a general description on the possible mechanism 
of action(s) of drug candidates along with their potential 
toxicities that may occur before they are clinically tested 
in humans (McGonigle & Ruggeri, 2014; Vogel & Vogel, 
2013).
Some animals commonly used in the pre-clinical 
testing of new drug candidates are mice, rats, guinea pigs, 
rabbits, cats, and dogs (Vogel & Vogel, 2013; Zuberi & 
Lutz, 2016). Phylogenetically, these animals have a close 
kinship with humans and therefore can provide suﬃcient 
and accurate information about the pathogenesis of 
diseases at the cellular and molecular levels (Vogel & 
Vogel, 2013). However, increasing concern on the animal 
welfare and awareness of the concept of animal rights has 
begun to limit the use of these animals in a pre-clinical 
research (Giacomotto & Ségalat, 2010; Pandey & Nichols, 




2011). This provides considerable pressure on researchers 
to immediately search for alternative model organisms 
that can be used in drug discovery research.
Several model organisms have been introduced as 
alternative in vivo platforms in the investigation of disease 
pathogenesis. One of the well-known model organisms 
is fruit ﬂy Drosophila melanogaster. This organism has 
already been widely used to generate disease models for 
several types of human diseases and to test new drug 
candidates (Fernández‐Hernández et al. 2016; Pandey & 
Nichols, 2011; Strange, 2016; Ugur et al. 2016). Drosophila 
enables researchers to complete screening of drug candi-
dates throughout by whole-animal experiments, a process 
diﬃcult using traditional animal models such as mice, 
rats, and rabbits (Giacomotto & Ségalat, 2010; Pandey & 
Nichols, 2011; Ugur et al. 2016).
In this article, we will discuss the use of Drosophila 
as a model organism in drug discovery research. The 
purpose of such discussion is to provide researchers 
with inspiration with which they think to start using 
Drosophila in their study on the pathogenesis of human 
diseases including neurodegenerative diseases, cancer, 
cardiovascular disorders, infectious diseases, and disor-
ders of metabolic syndrome such as obesity and diabetes 
mellitus. In addition to the above, the promising applica-
tion of D. melanogaster in the discovery of new drugs will 
be brieﬂy discussed. Furthermore, based on one author’s 
(F. N.) experience in pioneering research using Drosophila 
at the Faculty of Pharmacy, Hasanuddin University (Indo-
nesia), this model organism has great potential to be used 
by researchers in Indonesia because Drosophila can be 
kept for years using low-budget maintenance facilities 
which would not burden researchers in developing coun-
tries such as Indonesia.
WHY FRUIT FLY Drosophila melanogaster?
Fruit ﬂy, also commonly known as vinegar ﬂy, is an 
insect species in the Diptera order and the Drosophilidae 
family. This ﬂy became the center of attention after 
Thomas Hunt Morgan introduced its use as a model 
organism in genetic research early 1900s (Markow, 2015). 
Until now Drosophila has been widely applied to explain 
various important biological phenomena that are also seen 
in humans, ranging from the role of apoptosis in devel-
opment and immunity (Meier et al. 2000; Nainu et al. 
2015; 2017; Nonaka et al. 2017), the eﬀect of nutrition in 
regulating biological functions and individual age (Rajan 
& Perrimon, 2013), to the meaning of genetic defects 
against phenotypic disorders in organisms (Mackay, 2010; 
Nakanishi et al. 2011; Pandey & Nichols, 2011).
Drosophila is an invertebrate animal with a body size 
of about 3 mm (Panchal & Tiwari, 2017). The genome 
of the Drosophilidae family of insects is about 180 MB 
(megabases) that is divided into four chromosomes 
(Adams et al. 2000). With a small number of chromo-
somes, Drosophila becomes a preferred organism for the 
study on the mechanism of gene arrangement in a chro-
mosome, regulation of gene activities and functions, and 
the pattern of mutations in eukaryotic organisms (Pandey 
& Nichols, 2011; Ugur et al. 2016; Wangler et al. 2015). 
Despite its simplicity, Drosophila genome is about 75% 
similar to human genome (Chien et al. 2002; Pandey & 
Nichols, 2011; Reiter et al. 2001). These are the bases 
for the potential use of Drosophila as a model organism 
suitable for research on disease mechanisms and drug 
discoveries.
Experimentally, fruit ﬂy has several advantages. First, 
fruit ﬂy is very easy to maintain requiring relatively 
low costs compared to other model organisms including 
zebraﬁsh, mice, and rats (Giacomotto & Ségalat, 2010; 
Pandey & Nichols, 2011; Strange, 2016). This point is very 
beneﬁcial to researchers having a limited size of research 
funds. Second, a female ﬂy can produce 30-50 eggs every 
day, and each egg develops into an adult ﬂy within 10 
days. This is very diﬀerent from mice that only produce 
a small number of oﬀspring in 3-4 months (Panchal & 
Tiwari, 2017). Thus, the use of Drosophila facilitates reli-
able experimental results using large testing populations 
in a short period of time. Third, Drosophila has a short 
lifespan, 2-3 months. This is great advantage for studies 
of several biological processes such as the mechanism 
of aging (Brandt & Vilcinskas, 2013; He & Jasper, 2014; 
Sun et al. 2013). Finally, Drosophila can used in research 
without the requirement of ethical clearance (Panchal & 
Tiwari, 2017; Pandey & Nichols, 2011).
With a short lifespan of a few months, Drosophila 
lives shorter than mice, rats, rabbits, or humans. However, 
Drosophila experiences various phases of life as 
commonly found in other animals such as the embryonic 
phase, the juvenile phase (larvae), and the adult phase 
through a process called metamorphosis (Markow, 2015; 
Reaume & Sokolowski, 2006). Obviously, each develop-
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mental phase lasts only a short period of time: embryos 
develop into ﬁrst-instar larvae only in one day, and 
second-instar and third-instar larvae emerge in one and 
two days, respectively. And in the next 5 days, third-instar 
larvae develop into pupae, and adult ﬂies eclose from 
pupal case (Reaume & Sokolowski, 2006). 
Drosophila is a pioneer model organism in the iden-
tiﬁcation of genes related to biological functions whose 
counterparts are also important in eukaryotic organisms, 
including humans. Examples of such genes include 
homeobox genes that play a crucial role in the control of 
entire developmental processes (Carroll, 1995; Pearson et 
al. 2005), a gene called dnc that was the ﬁrst to be found 
important in learning processes (Dubnau & Tully, 1998), 
period whose identiﬁcation has led to the understanding 
of circadian rhythm (Konopka & Benzer, 1971), and 
Tl has brought us the mechanisms of innate immunity 
(Lemaitre et al. 1996; Medzhitov et al. 1997). To date, 
eight Nobel Prizes in Physiology or Medicine were given 
to researchers who work with this tiny insect (Patel & 
Prokop, 2017).
Drosophila DATABASES AND STOCK 
CENTERS
In many studies, especially those related to the 
discovery and mechanisms of action of new drugs, the 
use of model organisms having mutation and transgenic 
genotypes is critically important (Bolon, 2004; Brad & 
Elizabeth, 2002; Snaith & Törnell, 2002). ‘Mutant’ is a 
term to describe the altered status of genetic materials in 
test animals while the term ‘transgenic’ means the process 
of increasing or decreasing the expression level of the 
existing genetic information. In the case of Drosophila, 
various types of mutants and transgenic ﬂies can be 
generated easily owing to the availability of entire genetic 
manipulations (Adams et al. 2000; Hales et al. 2015; Li & 
Garza, 2004; Pandey & Nichols, 2011; Venken & Bellen, 
2007). Until now, Drosophila lines having alterations on 
almost all individual genes have been produced and are 
widely used in research (Venken & Bellen, 2007; Yama-
moto et al. 2014).
Drosophila is a model organism that has been success-
fully used for years in the screening of genes interested 
using either forward or reverse genetic methods (Hales 
et al. 2015). Forward genetics is a method to identify 
genes that are responsible for the emergence of certain 
phenotypes of researcher’s interest (Gibson & Muse, 
2009). For example, researchers may identify a gene 
responsible for converting the color of Drosophila’s 
eyes from red (mutant) to white (normal) using forward 
genetics. Conversely, reverse genetics is used to analyze 
phenotypes that emerge in model animals after altering 
genes of researcher’s interest (Gibson & Muse, 2009). For 
example, researchers may ﬁnd the roles of certain genes 
by looking at emerging phenotypes after introducing 
mutations on them.
The most important point in using Drosophila is to 
select appropriate lines with distinct genotypes. This 
is made possible through the use of organizations that 
distribute various types of Drosophila lines at low costs 
(Wangler & Bellen, 2017). For example, there are several 
wild-type strains from which researchers in the ﬁeld of 
drug discovery may choose a strain most suitable for their 
contexts. Researchers can directly contact relevant stock 
centers by telephone or emails. In addition to such stock 
centers, there are researcher-based organizations, such 
as Drososhare in Europe, where dedicated researchers 
are in charge of distributing Drosophila lines to other 
researchers all over the world. The delivery of Drosophila 
can be done using ordinary postal packages, registered 
postal packages, or special postal packages with a custom-
ized delivery period.
Drosophila AS A SUITABLE ORGANISM 
FOR HUMAN DISEASE MODEL
To facilitate research on disease pathophysiology and 
drug discovery, the availability of human disease models 
is of a great help. Although the size and appearance of 
Drosophila are quite diﬀerent from those of humans, 
this insect has been frequently used in various types of 
research to study the pathogenesis of human diseases 
(Pandey & Nichols, 2011; Reiter, 2005; Ugur et al. 2016). 
The use of Drosophila has provided important knowledge 
regarding the pathogenesis of various human diseases at 
cellular and molecular levels (Wangler & Bellen, 2017; 
Wangler et al. 2015). Accumulating information from 
such research is certainly very valuable in ﬁnding and 
tracing the working mechanism of new drug candidates.
1. Drosophila as a model organism to study 
cancer
Drosophila has made great contribution to studies on 
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the mechanism of the emergence of cancer and ways that 
can be used to overcome it (Gonzalez, 2013; Sonoshita 
& Cagan, 2017). A large number of genes and signaling 
pathways are involved in the creation and maintenance 
of our body. Any mistakes in gene expression and 
signal pathways could cause abnormal growth of cells 
called cancer, an event that was ﬁrst discovered and 
characterized in Drosophila (Gonzalez, 2013; Sonoshita 
& Cagan, 2017). Examples of this kind are signaling 
pathways called Hedgehog and Hippo. Tumor develops 
in Drosophila when these pathways are impaired. Studies 
with Drosophila cancer models until now have shown 
that the process of cancer development in Drosophila 
and humans bear a striking resemblance to each other 
(Brumby & Richardson, 2005; Gonzalez, 2013; Rieder & 
Larschan, 2014; Wangler et al. 2015). In general, cancer 
in humans results from the uncontrolled growth of epithe-
lial cells (Christofori & Semb, 1999). Using Drosophila, 
researchers have studied epithelial cell-derived cancer 
(Brumby & Richardson, 2005; Pandey & Nichols, 
2011). There are four main hallmarks of cancer: uncon-
trolled cell division, resistance to cell growth-inhibiting 
signals, resistance to apoptosis-inducing signals, and 
migration and colonization at various places, referred 
as metastasis. All these hallmarks can be studied using 
Drosophila (Brumby & Richardson, 2005; Christoﬁ & 
Apidianakis, 2013; Gonzalez, 2013). Most oncogenes 
and tumor suppressor genes responsible for the control 
of cancer in humans possess counterparts in Drosophila. 
The signaling pathway involving the oncogene product 
Ras was found for the ﬁrst time in the visual system of 
Drosophila (Olivier et al. 1993; Simon et al. 1991), and 
this pathway plays an important role in the development 
of cancer in humans (Bier, 2005; Shaw & Cantley, 2006). 
Mutations in tumor suppressor genes scribble, disc large 
1, and lethal (2) giant larvae in Drosophila induce cancer 
with all markers seen in humans, including metastatic 
processes metastasis (Brumby & Richardson, 2005).
The compound eye of Drosophila is often used as 
tissues to induce cancer (Miles et al. 2011; Rudrapatna 
et al. 2012). Drosophila eyes are made up of about 800 
hexagon ommatidia, called facets, with "smooth" surface 
structures (Kumar, 2012). When cancer is induced, the 
surface of eyes is not smooth anymore and called "rough" 
eyes. This easy-to-ﬁnd phenotype is widely used in the 
study of cancer pathogenesis as well as to examine the 
eﬀectiveness of various treatments (Miles et al. 2011; 
Pandey & Nichols, 2011; Rudrapatna et al. 2012). Also, 
a test for survival of larvae and pupae is often taken to 
monitor the severity of cancer (Pandey & Nichols, 2011; 
Willoughby et al. 2013). In such studies, larvae bearing 
cancer, which is labeled with GFP, are placed in a 96-well 
plate, treated with drug candidates, and maintained for 
certain periods of time. The eﬀectiveness of drug candi-
dates is determined in two parameters: the number of 
survived larvae and the intensity of GFP ﬂuorescence: 
GFP intensity is proportional to the rate of cancer growth 
(Pandey & Nichols, 2011; Reiter, 2005; Willoughby et al. 
2013). Although Drosophila seems to be an ideal model 
organism for the study of cancer, there is a limitation: 
not all types of cancer found in humans can develop in 
Drosophila such as prostate cancer and breast cancer 
(Pandey & Nichols, 2011).
2. Drosophila as a model of neurodegenerative 
diseases
Since its introduction in the early 20th century by 
Thomas Hunt Morgan, Drosophila has been one of the 
favorite model organisms in a study on the anatomy and 
physiology of the nervous system in eukaryotes, including 
mammals (Bellen et al. 2010; Hales et al. 2015; Reiter, 
2005). For example, mutations in a gene coding for Notch 
were identiﬁed in 1915 and reported a year later as a 
mutation that causes wing malformations in Drosophila 
(Bellen et al. 2010). This discovery paved the way for 
subsequent discoveries, including Delta as a Notch ligand. 
Eventually, the Notch signaling pathway in Drosophila 
and similar pathways in vertebrates, including humans, 
have been shown to play an important role in neural 
activities (Bellen et al. 2010).
An advantage in using fruit ﬂy is that neurons can 
be completely removed without killing animals. In addi-
tion, any human genes in question can be expressed at 
certain time points and certain tissues (Pandey & Nichols, 
2011; Reiter, 2005). Furthermore, the detection of gene 
products, i.e., proteins and mRNAs, in Drosophila is 
easier than in mice and rats. The expression patterns of 
gene interested can be determined by in situ detection of 
mRNA and monitoring tags fused to cognate proteins. 
Finally, Drosophila is a relatively short-living and thus 
suitable to monitor the pathogenesis of neurodegenerative 
diseases (Pandey & Nichols, 2011).
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Using Drosophila researchers can conduct both gain-
of-function and loss-of-function experiments more easily 
than using other model animals. Once Drosophila lines 
showing interesting phenotypes related neuronal actions, 
researchers carry out ‘rescue’ experiments by ectopi-
cally expressing candidate genes, even human genes, in 
a speciﬁc spatio-temporal manner. Also, researchers can 
screen a library of Drosophila lines that have lost candi-
date genes to ﬁnd lines showing phenotypes of interest. 
However, it should be noted that not all Drosophila mutants 
survive until adulthood, and that phenotypes produced by 
mutating interesting genes in Drosophila might not those 
expected from human diseases (Reiter, 2005). 
Drosophila has been used extensively to study 
biochemical and genetic processes that occur in eukary-
otic nervous system (Bellen et al. 2010; Hales et al. 
2015; Wangler et al. 2015). Particularly, Drosophila is 
now extensively used to investigate neurodegenerative 
diseases including Alzheimer’s disease, Parkinson’s 
disease, Huntington’s disease, epilepsy, and amyotrophic 
lateral sclerosis (Pandey & Nichols, 2011; Reiter, 2005; 
Wangler & Bellen, 2017; Yamamoto et al. 2014). From 
such research, we have so far learned that most neuro-
degenerative diseases caused by the progressive loss of 
speciﬁc neurons are closely related to the formation of 
toxic protein aggregates in intracellular environments 
(Pandey & Nichols, 2011; Reiter, 2005). Also, as known 
for humans, the emergence of neurodegenerative diseases 
in Drosophila becomes frequent as animals age (Bonner 
& Boulianne, 2011).
3. Drosophila as a model to study infectious 
diseases
Like most other insects, Drosophila is only equipped 
with the innate immune system (Hoﬀmann, 2003) 
of which structure is, unexpectedly, quite similar to 
humans’ (Buchon et al. 2014; Hoﬀmann, 2003). There-
fore, Drosophila has been used to investigate the basic 
mechanisms of the innate immune system of humans. 
In addition, Drosophila has helped to solve the genetic 
control of immune system under infectious states (Buchon 
et al. 2014; Imler, 2014).
Drosophila immune system is divided, as is mammals’, 
into two parts; cellular and humoral responses (Elrod-
Erickson et al. 2000; Royet et al. 2003). At the cellular 
level, Drosophila is protected by cellular immunity 
through the actions of hemocytes, Drosophila blood cells, 
which exist in the form of plasmatocytes, lamellocytes, 
and crystal cells (Lemaitre & Hoﬀmann, 2007; Parsons 
& Foley, 2016). Plasmatocytes, spherical cells with a 
diameter of about 10 µm, function similarly to mamma-
lian macrophages being responsible for the phagocytic 
elimination of invading bacteria (Chung & Kocks, 2011; 
Nonaka et al. 2013; Shiratsuchi et al. 2012) and viruses 
(Zhu & Zhang, 2013) as well as cells undergoing physi-
ological (Franc et al. 1999; Nonaka et al. 2017; Nonaka et 
al. 2013) or virus-induced (Lamiable et al. 2016; Nainu et 
al. 2015) apoptosis. Extensive studies have clariﬁed how 
Drosophila innate immune system involving plasmato-
cytes recognizes pathogens in a mechanism resembling 
humans’ (Buchon et al. 2014; Gold & Brückner, 2015; 
Lemaitre & Hoﬀmann, 2007; Nainu et al. 2017; Wang et al. 
2013). Also, the analysis of lamellocytes and crystal cells 
has provided information regarding a defense against para-
sitic infections and melanization processes (Lemaitre & 
Hoﬀmann, 2007). To induce humoral immune responses, 
Drosophila activates signaling pathways known as the 
Toll and Imd pathways that are connected with the induc-
tion of transcription, apoptosis, autophagy, and RNA 
interference (Buchon et al. 2014; De Gregorio et al. 2002; 
Karlikow et al. 2014; McPhee & Baehrecke, 2009; Merk-
ling & van Rij, 2013; Myllymäki et al. 2014; Usmar et 
al. 2017; Valanne et al. 2011; Xu & Cherry, 2014; Zeidler 
et al. 2000). All these events lead to the production of 
soluble proteins that counteract pathogenic attacks, such 
as bacteria, fungi, and viruses.
Researchers have infected Drosophila with bacteria 
that cause human diseases (Panayidou et al. 2014) to 
examine the eﬀectiveness of antibiotic compounds such 
as tetracycline and amoxicillin (Apidianakis & Rahme, 
2009; Ben-Ami et al. 2013; Needham et al. 2004). 
Adopting this strategy, Drosophila is now used to test 
the activity of natural compounds derived from plants as 
antibacterial (Nainu et al. 2018) or antiviral (Ekowati et 
al. 2017) agents. A variety of Drosophila mutants enable 
researchers to test candidate compounds in immune-
compromised animals in a rapid, simple, and economical 
manner.
4. Drosophila as a model of metabolic syndrome 
disorders
Obesity and related metabolic disorders such as 
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diabetes mellitus are still one of the highest causes of 
death in the world (Arroyo-Johnson & Mincey, 2016; 
Zheng et al. 2017). Seeing this trend, the discovery of 
more eﬀective drugs is urgently needed. The generation 
of a Drosophila model of diabetes mellitus should be of 
tremendous help (Alfa & Kim, 2016; Graham & Pick, 
2017). It should be noted that Drosophila does not have 
pancreatic organs, and its physiology is quite diﬀerent 
from humans’. However, at the level of individual cells, 
there exists a huge functional resemblance to humans (Alfa 
& Kim, 2016). For example, Drosophila contains a protein 
named Drosophila insulin-like protein (DILP) equivalent 
to insulin (Alfa & Kim, 2016; Nässel et al. 2013). Destruc-
tion of DILP-producing cells causes an increase in the 
levels of glucose and lipids in hemolymph, body ﬂuids 
of Drosophila. This means that Drosophila experiences 
diabetes-like symptoms, suggesting Drosophila as a suit-
able model animal for studying the pathophysiology of 
diabetes and related diseases (Alfa & Kim, 2016; Palanker 
Musselman et al. 2011; Pandey & Nichols, 2011; Rulifson 
et al. 2002). Reduced expression of DILP has negative 
eﬀects on the growth of Drosophila making the size of 
larvae and adults smaller (Kannan & Fridell, 2013; Ruaud 
& Thummel, 2008; Rulifson et al. 2002). Therefore, body 
size is a potential phenotypic indicator in the screening 
of drug candidates against metabolic diseases (Pandey & 
Nichols, 2011). Furthermore, Drosophila possesses recep-
tors homologous to sulfonylurea receptors in humans, 
which function to control a glucose balance. Thus, 
Drosophila can be used in high throughput screening 
of drug candidates anticipating a mechanism similar to 
glibenclamide or drugs in the sulfonylurea group (Pandey 
& Nichols, 2011).
Drosophila has been used in a study on the relationship 
between nutrition and obesity (Musselman & Kühnlein, 
2018). To generate an obesity model, Drosophila is fed 
with a diet of high triglyceride content. Under such a diet 
condition, Drosophila dramatically gains weight and 
reduces movement, and eventually its life span is short-
ened (J. Hoﬀmann et al. 2013). Also, feeding Drosophila 
with a high content of fatty acids (derived from coconut 
oil) creates a phenotype resembling metabolic syndromes. 
Interestingly, a glucose status is inﬂuenced by the dura-
tion of feeding with saturated fatty acids: feeding for a 
short period decreases glucose levels associated with 
increased levels of DILP. In contrast, prolonged feeding 
induces an increase in the level of glucose and a decrease 
in insulin responses, as commonly found with patients 
suﬀering from type 2 diabetes mellitus (Birse et al. 2010). 
Certainly, the use of a Drosophila model in an eﬀort to 
discover new drugs to treat metabolic syndromes is prom-
ising (Men et al. 2016; Pandey & Nichols, 2011; Smith et 
al. 2014).
PROSPECT OF Drosophila AS A MODEL 
ORGANISM IN DRUG DISCOVERY
At present, researchers have used Drosophila as an in 
vivo platform for screening drug candidates. An advan-
tage of this insect is that we can obtain results in a short 
time at low cost (Pandey & Nichols, 2011). A research 
group led by Ross Cagan conducted a pre-clinical test of 
drug candidates with Drosophila without an in vitro test 
using cell cultures or other in vitro platforms (Vidal et al. 
2005) and successfully identiﬁed Vandetanib (ZD6474) 
that was approved by US FDA for the treatment of medul-
lary thyroid carcinoma in 2011.
When examining the pharmacological eﬀects of new 
drug candidates, the route of administration needs to be 
chosen. There are several administration routes feasible 
with Drosophila, and a choice is dependent on at which 
developmental stages Drosophila is used. For example, 
embryos may be administered with drugs by a permeabi-
lization method while larvae and adults are fed with food 
that contains drugs. Adult ﬂies may also be administered 
with drugs in the form of vapor and by injection directly 
into the body cavity. In some cases, larve and adults are 
given drugs that are dissolved in glucose-containing water 
and absorbed in a ﬁlter paper (Pandey & Nichols, 2011).
The fruit ﬂy Drosophila melanogaster is an ideal 
model animal in research toward drug discovery because 
it resembles humans in genetic materials, physiology, 
pathology, and reactions to medications. Various biolog-
ical processes seen in human bodies can be studied using 
Drosophila, such as gene expression, reproduction, body 
development y, cell division and diﬀerentiation, cell death, 
energy metabolisms, and immunity. However, we had 
better be careful because none of model animals cannot 
be absolutely the same as humans. In fact, Drosophila and 
humans diﬀer in the size and organization of body that 
sometimes become a limitation on the use of this model 
organism in research. For example, due to the absence of 
blood vessels in Drosophila, testing the eﬀects of drugs 
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on hemostasis is rather diﬃcult. Also, we are unable to 
discover drugs that function through study adaptive 
immunity that is absent in Drosophila.
CONCLUSION
Drosophila has been used as a model organism in 
genetic research for more than 100 years. Many researchers 
now consider Drosophila as a tool for generating human 
disease models and subsequent pharmacological testing of 
new drug candidates. Thanks to the availability of various 
genetic approaches and less time-consuming operations 
in generating mutants and transgenic genotypes, the use 
of Drosophila will be expanding and promising. We will 
identify and annotate many uncharacterized human genes 
using Drosophila as a surrogate creature. Also, we will 
rapidly complete the screening of candidate substances at 
a pre-clinical level and surely obtain novel drugs to cure 
intractable human diseases.
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